Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.

Adenoviridae / physiology Animals Cell Line, Tumor Cytotoxicity, Immunologic Humans Mice Molecular Targeted Therapy Neoplasm Metastasis Oncolytic Viruses / physiology Rabbits Retinoblastoma / immunology Retinoblastoma Protein / metabolism Signal Transduction Survival Analysis Tissue Distribution Translational Research, Biomedical Treatment Outcome Virus Replication Xenograft Model Antitumor Assays

Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
23 01 2019
Historique:
received: 13 06 2018
accepted: 22 12 2018
entrez: 25 1 2019
pubmed: 25 1 2019
medline: 23 2 2020
Statut: ppublish

Résumé

Retinoblastoma is a pediatric solid tumor of the retina activated upon homozygous inactivation of the tumor suppressor

Identifiants

DOI: 10.1126/scitranslmed.aat9321 PMID: 30674657
pubmed: 30674657
pii: 11/476/eaat9321
doi: 10.1126/scitranslmed.aat9321
pii:
doi:

Substances chimiques

Retinoblastoma Protein 0

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Guillem Pascual-Pasto (G)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
ORCID: 0000-0001-8537-261X

Miriam Bazan-Peregrino (M)

VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.
ORCID: 0000-0001-7367-8304

Nagore G Olaciregui (NG)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Camilo A Restrepo-Perdomo (CA)

Pathology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Ana Mato-Berciano (A)

VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.

Daniela Ottaviani (D)

Institut Curie, CNRS, UMR144, SIREDO Oncology Center, 75248 Paris, France.
Institut Curie, PSL Research University, 75248 Paris, France.

Klaus Weber (K)

AnaPath GmbH, Oberbuchsiten 4625, Switzerland.
ORCID: 0000-0002-9356-3480

Genoveva Correa (G)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Sonia Paco (S)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Monica Vila-Ubach (M)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Maria Cuadrado-Vilanova (M)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Helena Castillo-Ecija (H)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
ORCID: 0000-0003-3861-6479

Gaia Botteri (G)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
ORCID: 0000-0002-3753-8117

Laura Garcia-Gerique (L)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Helena Moreno-Gilabert (H)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
ORCID: 0000-0003-4950-4237

Marta Gimenez-Alejandre (M)

VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.

Patricia Alonso-Lopez (P)

VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.

Marti Farrera-Sal (M)

VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.
ORCID: 0000-0002-8170-1276

Silvia Torres-Manjon (S)

Translational Research Laboratory, IDIBELL-Institut Catala d'Oncologia, 08908, L'Hospitalet de Llobregat, Barcelona, Spain.

Dolores Ramos-Lozano (D)

Translational Research Laboratory, IDIBELL-Institut Catala d'Oncologia, 08908, L'Hospitalet de Llobregat, Barcelona, Spain.

Rafael Moreno (R)

Translational Research Laboratory, IDIBELL-Institut Catala d'Oncologia, 08908, L'Hospitalet de Llobregat, Barcelona, Spain.
ORCID: 0000-0001-9957-3105

Isabelle Aerts (I)

Institut Curie, CNRS, UMR144, SIREDO Oncology Center, 75248 Paris, France.
Institut Curie, PSL Research University, 75248 Paris, France.

François Doz (F)

Institut Curie, CNRS, UMR144, SIREDO Oncology Center, 75248 Paris, France.
Paris Descartes University, 75006 Paris, France.
ORCID: 0000-0001-9286-4831

Nathalie Cassoux (N)

Institut Curie, CNRS, UMR144, SIREDO Oncology Center, 75248 Paris, France.
Paris Descartes University, 75006 Paris, France.
Institut Curie, Ophthalmic Oncology, 75248 Paris, France.
ORCID: 0000-0002-5535-9649

Elodie Chapeaublanc (E)

Institut Curie, CNRS, UMR144, SIREDO Oncology Center, 75248 Paris, France.
Institut Curie, PSL Research University, 75248 Paris, France.
ORCID: 0000-0002-9668-7753

Montserrat Torrebadell (M)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
ORCID: 0000-0002-0027-3215

Monica Roldan (M)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pathology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Andrés König (A)

Vivotecnia Research S.L., Tres Cantos, Madrid 28760, Spain.

Mariona Suñol (M)

Pathology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Joana Claverol (J)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Clinical Trials Unit, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Cinzia Lavarino (C)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Torres Carmen de (T)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Ligia Fu (L)

Pediatric Hematology-Oncology, Hospital Escuela Universitario, Tegucigalpa, Honduras.

François Radvanyi (F)

Institut Curie, CNRS, UMR144, SIREDO Oncology Center, 75248 Paris, France.
Institut Curie, PSL Research University, 75248 Paris, France.

Francis L Munier (FL)

Hôpital Ophtalmique Jules-Gonin, Lausanne 133, Switzerland.

Jaume Catalá-Mora (J)

Ophthalmology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
ORCID: 0000-0003-2152-8579

Jaume Mora (J)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

Ramón Alemany (R)

Translational Research Laboratory, IDIBELL-Institut Catala d'Oncologia, 08908, L'Hospitalet de Llobregat, Barcelona, Spain.

Manel Cascalló (M)

VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.

Guillermo L Chantada (GL)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
Hospital de Pediatria JP Garrahan, Buenos Aires 1245, Argentina.
CONICET, Buenos Aires 1245, Argentina.
ORCID: 0000-0002-9375-9336

Angel M Carcaboso (AM)

Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain. amontero@fsjd.org.
Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.
ORCID: 0000-0002-8485-426X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Virus › Virus à ADN › Adenoviridae › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Eucaryotes › Animaux › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Phénomènes du système immunitaire › Cytotoxicité immunologique › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Virus › Virus oncolytiques › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Lagomorpha › Lapins › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Maladies de l'oeil › Rétinopathies › Tumeurs de la rétine › Rétinoblastome › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine du rétinoblastome › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Disciplines des sciences naturelles › Science › Recherche › Recherche biomédicale › Recherche médicale translationnelle › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Therapeutic targeting of the RB1 pathway in...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Therapeutic targeting of the RB1 pathway in...